FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to neurology, and concerns treating olfactory dysfunction. To do so rasagiline or its pharmaceutically acceptable salt in therapeutically effective amount are administered.
EFFECT: this provides effective treatment of olfactory dysfunction, including one not caused by Parkinson's disease.
13 cl, 7 dwg, 33 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RASAGILINE COMPOSITIONS WITH PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2734632C2 |
| AGENT IMPROVING PROCESS OF TRAINING, MEMORY AND COGNITIVE FUNCTIONS, AS WELL AS FOR SYMPTOMATIC THERAPY AT AUTISTIC DISORDERS | 2015 |
|
RU2612791C1 |
| RASAGILINE COMPOSITIONS OF PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2607595C2 |
| AGENT FOR TREATING AND PREVENTING DISORDERS OF AUTISM SPECTRUM | 2015 |
|
RU2608444C1 |
| PEPTIDE HAVING LYNX1 PROTEIN ACTIVITY (EMBODIMENTS), PHARMACEUTICAL COMPOSITION FOR TREATING ANXIETY DISORDERS AND DEPRESSION OR CORRECTION OF COGNITIVE DISORDERS IN NEURODEGENERATIVE DISEASES, CONTAINING SAID PEPTIDE, AND METHOD OF TREATING AND CORRECTING SAID DISORDERS | 2020 |
|
RU2734649C1 |
| COMPOSITIONS OF RASAGILINE WITH IMPROVED HOMOGENEITY OF CONTENT | 2006 |
|
RU2404746C2 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING NEURONAL APOPTOSIS OR NEURODEGENERATION | 2011 |
|
RU2586772C2 |
| AGENT FOR TREATING PARKINSON'S DISEASE | 2024 |
|
RU2839611C1 |
| ALPHA-SYNUCLEIN MODULATORS | 2018 |
|
RU2797677C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
